MINNEAPOLIS, Aug. 15, 2011 (GLOBE NEWSWIRE) -- PuraMed BioSciences, Inc. (OTCQB:PMBS) has chosen Media Relations, Inc. to create consumer awareness and excitement nationally for LipiGesic M, the company's new non-prescription migraine treatment, which independent clinical research has shown to be a highly effective first-line therapy for migraines.
Media Relations (www.publicity.com), the nation's leading performance-based public relations agency, is recognized worldwide for its expertise in launching and branding products within the health and nutrition industries.
"We chose the Media Relations team because I was impressed with the depth and breadth of their understanding of our industry," says PuraMed BioScience CEO Russell Mitchell. "I have watched what they have accomplished with other brands over the years, and I am very excited to be working with them as we bring this important, breakthrough product into the public arena."
The consumer awareness campaign will include extensive public relations and social media elements. "We are very excited to begin applying our proven tactical strategies, and to harness our North American network of media contacts, to educate migraine sufferers about this latest over-the-counter migraine treatment," confirms Media Relations Health and Nutrition Division Vice President Mike Danielson. "We are developing a team of third-party expert resources for the media that will include medical doctors, pharmacists and celebrities in combination with the leading researchers responsible for the recent clinical study." He adds, "We will also capitalize on social media channels, using consumer messaging designed to support retail pull-through as LipiGesic M's distribution expands to mainstream stores."
Danielson says, "We predict that LipiGesic M will have tremendous appeal because the product's formulation is great intellectual property backed by world-class research."
A study conducted by leading headache researcher Dr. Roger Cady confirming LipiGesic M's efficacy has been published in the 'Early View' section of the online and July/August print editions of Headache, a top-tier medical journal of the American Headache Society.
The multi-site, double-blind, placebo-controlled study was conducted with the assistance of two additional nationally recognized investigators: Jerome Goldstein, MD of San Francisco and Robert Nett, MD, RPh of San Antonio.
The researchers found that 64 percent of subjects found pain relief within two hours of taking LipiGesic M. The study concludes that the medication's combination of sublingual feverfew/ginger appears safe and effective as a first-line treatment for a population of migraine sufferers who frequently experience a mild headache prior to the onset of a moderate or severe headache.
"We are pleased to work with Media Relations, Inc. to help spread the word about these important study results, and we look forward to capitalizing their ability to raise awareness among consumers that now there is a more effective, accessible and affordable treatment for migraines," says Mitchell.
For additional information on LipiGesic M, visit www.LipiGesicM.com.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.